About: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.11 (-5.13%)
SPRO NASDAQ Spero Therapeutics Inc
Spero Therapeutics Inc share price
Atividade de preço de SPRO
Último preço
$ 1,110
Variação (24h)
-0,06 USD (5,13%)
Volume
209.41K
Volume (média 4 sem.)
-
Abertura
$ 1,18
Variação do dia
$ 1,11 - $ 1,18
Fechamento anterior
$ 1,17
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
SPRO price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals